For pharma and biotech companies there are many advantages to partnering with a CDMO: they can access more specialized knowledge, state-of-the-art equipment and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market. Much of the innovation in pharma pipelines is currently driven by smaller – or even virtual – companies. These companies often have limited in-house resources for product development or scale up, and depend on CDMO partnerships to achieve development milestones. To meet these expectations, Contract Development and Manufacturing Organizations (CDMOs) need to provide the right expertise, the right capabilities, and the right regulatory experience to help their customers bring products to market quickly, efficiently and cost effectively. As both a CDMO and a manager of CMOs, Avéma has seen 8 trends emerge.
Download this White Paper to learn more.
|
